NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Vistagen Therapeutics, Inc. (VTGN) Stock Analysis

Vistagen Therapeutics, Inc. (VTGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VTGN

$0.24

−$0.01 (−4.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VTGN with… →

VTGN Key Statistics

As of Sep 4, 2026
Trading
Open
$0.25
Previous Close
$0.25
Day's Range
0.24–0.26
52-Week Range
0.20–5.14
Volume
347.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.39
Valuation
Market Cap
$10.77M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.31
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.66
Financials (FY)
Revenue (FY)
$1.27M+161.11%
Net Income (FY)
−$69.69M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
44.38M
1-Year Return
−93.37%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
4.08M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VTGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−63.64%
2025−77.63%
2024−42.61%
2023+71.33%
2022−94.87%
2021+0.52%
2020+181.16%
2019−54.00%
2018+35.14%
2017−70.24%
2016 (partial year)+25.59%

As of September 4, 2026.

VTGN Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$1.27M−$69.69M−5491.3%
2024$486.00K−$51.42M−10579.8%
2023$1.06M−$29.36M−2759.6%
2022−$227.00K−$59.25M26100.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.27M—−$72.13M−$69.69M−5491.3%
2024$486.00K—−$55.97M−$51.42M−10579.8%
2023$1.06M—−$33.02M−$29.36M−2759.6%
2022−$227.00K—−$59.27M−$59.25M26100.4%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

VTGN Valuation vs Biotechnology Median

Median of 656 stocks
MetricVTGNBiotechnology medianvs median
P/S ratio4.3115.260.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Vistagen Therapeutics, Inc. (VTGN) at $10.77M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 41.

The 52-week range on file runs from $0.20 to $5.14. VTGN last closed at $0.24 on September 4, 2026. That is −$0.01 (−4.00%) against the previous close. The latest close sits 20% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.27M. Against the prior fiscal year total of $486.00K, that is a change of +161.11%. The same year closed with a net loss of $69.69M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.66.

Across the 4 fiscal years on file, revenue moves from −$227.00K in 2022 to $1.27M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 4.31 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −93.37%. Across 10 years the annualized return works out at −45.76%. The reported beta is 0.39. Daily returns over the trailing 10 years annualize to a volatility of 241.55%.

Growth & Income

No dividend is on file for VTGN.

Across the complete calendar years on file, 2020 returned +181.16% and 2022 returned −94.87%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −63.64% year to date.

Peer Comparison

Vistagen Therapeutics, Inc. (VTGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vistagen Therapeutics, Inc. VTGN $10.77M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Vistagen Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Visit website →